Date | Title | Description |
19.07.2024 | The Week’s 10 Biggest Funding Rounds: Cardurion Pharmaceuticals And Human Interest Nab Largest Raises | 5 Shares Email Facebook Twitter LinkedIn
Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board.
This is a w... |
19.03.2024 | NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting | SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced th... |
11.03.2024 | NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results | - |
11.03.2024 | NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results | --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected c... |
26.02.2024 | NGM to go private as part of $135M buyout by VC firm Column Group | Following a year that saw a third of staff laid off and a sliding share price, NGM Bio has decided to go private as part of a $135 million buyout by VC firm The Column Group.
A special committee of “independent and disinterested directors” ... |
20.02.2024 | NGM Bio to Participate in the Cowen 44th Annual Health Care Conference | SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J.... |
25.05.2023 | NGM Bio to Participate in Upcoming Investor Conferences | /EIN News/ -- SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today ... |
08.05.2023 | NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Ma... | Aldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid synthesis) and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-D
Around 25-50% of patients with diarrhea-predominant ... |
04.05.2023 | NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data | Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with ... |
25.03.2023 | Her doctor said her severe morning sickness was all in her head – but this scientist wanted to find the truth | Taped above a tidy wooden desk in the corner of her bedroom, right at eye level, is a piece of paper that Marlena Fejzo has saved for 24 years.
It’s a portrait of Dr Fejzo at age 31 during the worst ordeal of her life. Her face and body are... |
04.11.2022 | NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting | /EIN News/ -- --Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive... |
17.10.2022 | NGM Bio’s Merck-partnered drug for vision loss disorder flunks Phase 2 test | After NGM Biopharmaceuticals’ most advanced internal program flunked a mid-stage study last year, the biotech said it would shift its focus to drug candidates covered by a partnership with Merck, including an antibody in clinical developmen... |
17.10.2022 | NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham
NGM621 showed favorable safety and tolerability, with no evidence of increased CNV c... |
16.10.2022 | NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration | SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline e... |
13.09.2022 | NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer... | NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 + gemcitabine + Nab-pacli... |
06.09.2022 | NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors ... | NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer
NGM120 has been well tolerated to date in patients in the Phase 1a study with no dose-limiting toxicities
Two of five ... |
15.08.2022 | NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology ... | Poster presentation at upcoming ESMO Annual Congress to highlight analysis of subgroup of patients with prostate cancer in NGM120 Phase 1a trial
Short-talk presentation at upcoming AACR Special Conference: Pancreatic Cancer to highlight ana... |
04.08.2022 | NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results | --Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with advanced solid tumors--
--Initiated the Ph... |
30.06.2022 | NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer | -- William J. Rieflin to transition from Executive Chairman to Chairman of the Board of Directors --
SOUTH SAN FRANCISCO, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology compan... |
23.06.2022 | NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022 | --NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy, will be showcased in the fourth of a four-part series titled the “Explorer Series”--
SOUTH... |
24.05.2022 | NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022 | --NGM707, NGM Bio’s most advanced myeloid reprogramming antibody product candidate, will be showcased in the third of a four-part series titled the “Explorer Series”--
SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- NGM Biopha... |
12.05.2022 | NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors | --Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA®--
--All three of NGM Bio’s wholly-owned myeloid reprogrammin... |
20.04.2022 | NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022 | SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it... |
08.04.2022 | NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio | ILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an immune-suppressive state in the tumor microenvironment
NGM707, NGM831 and NGM438 are all engineered to release myeloid checkpoints and reprog... |
31.03.2022 | NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors | Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and expected to enroll up to approximately ... |
21.03.2022 | NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022 | --The four-part series titled the “Explorer Series” will showcase NGM Bio’s discovery engine, myeloid reprogramming and checkpoint inhibition portfolio and program for the treatment of geographic atrophy--
SOUTH SAN FRANCISCO, Calif., March... |
10.01.2022 | NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs | After a transformative year in 2021, NGM Bio enters 2022 with a diverse pipeline of seven disclosed programs, including four programs in Phase 2 trials and a wholly-owned oncology portfolio
Anticipated milestones in 2022 include:
Topline da... |
10.01.2022 | NGM Biopharmaceuticals : Bio - JPM 2022 Presentation | TM
Biology-driven discovery. Life-changing medicines.
Corporate Overview
January 2022
NASDAQ: NGM
©2022 NGM Bio
Safe Harbor Statement
The following presentation contains forward-looking statements, including, but not limited to, statements ... |
10.01.2022 | NGM Biopharmaceuticals : Bio Corporate Presentation January 2022 | TM
Biology-driven discovery. Life-changing medicines.
Corporate Overview
January 2022
NASDAQ: NGM
©2022 NGM Bio
Safe Harbor Statement
The following presentation contains forward-looking statements, including, but not limited to, statements ... |
06.12.2021 | NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab) | NGM entered into a clinical trial collaboration and supply agreement with Merck to evaluate the potential of NGM707 in combination with KEYTRUDA for the treatment of patients with advanced or metastatic solid tumors
NGM707 is part of NGM’s ... |
06.12.2021 | NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck's KEYTRUDA® (pembrolizumab) | NGM entered into a clinical trial collaboration and supply agreement with Merck to evaluate the potential of NGM707 in combination with KEYTRUDA for the treatment of patients with advanced or metastatic solid tumors
NGM707 is part of NGM’s ... |
23.08.2021 | NGM Biopharmaceuticals : Bio Discloses Fourth Oncology Development Candidate, 831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research | Publication describes NGM’s discovery of ILT3’s functional ligand, fibronectin, a key component of the tumor stroma
ILT3-fibronectin interactions within the tumor microenvironment may form a stromal checkpoint that actively suppresses myelo... |
22.07.2021 | NGM Biopharmaceuticals : Announces Completion of Enrollment in Phase 2 CATALINA Study of 621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration | Geographic atrophy is a progressive, irreversible retinal degenerative disease that can lead to blindness, with no currently approved treatmentsNGM621 is a monoclonal antibody against complement C3, a protein implicated in the pathophysiolo... |
24.05.2021 | NGM Bio’s NASH drug fails in Phase 2; focus shifts to Merck-partnered programs | An experimental NGM Biopharmaceuticals treatment for non-alcoholic steatohepatitis, the fatty liver disease more commonly referred to as NASH, has failed in clinical testing, a surprising result considering that an earlier mid-stage study s... |
28.04.2021 | NGM BIOPHARMACEUTICALS, INC.
NGM BIOPHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In connection with the 2021 annual meeting of stockholders (the "2021 Annual ... |
28.04.2021 | NGM BIOPHARMACEUTICALS, INC.
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors | SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today the no... |
04.03.2021 | NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results | • Significant progress made across liver and metabolic diseases, retinal diseases and cancer during fourth quarter 2020:
• Presented first-in-human results from Phase 1 clinical trial of NGM621 in patients with geographic atrophy (GA) at th... |
25.02.2021 | NGM Bio to Present at the Cowen 41st Annual Health Care Conference | SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Da... |
13.02.2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | South San Francisco-based NGM Bio may have underwhelmed with its interim analysis of a key cohort from a mid-stage NASH study last fall — but stellar topline data unveiled on Monday showed the compound induced significant signs of antifibro... |
06.01.2021 | Jan 5, 2021 - NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock | - |
19.11.2020 | NGM Biopharmaceuticals : Investor Day - Presentation | © 2017 Copyright. NMI Holdings Inc.
2020 Virtual Investor Day
Welcome to NMI Holdings, Inc. - 2020 Virtual Investor Day
Presentation materials will be displayed on screen alongside a video of management through each section of today's discu... |
19.11.2020 | NGM BIOPHARMACEUTICALS, INC.
NGM Biopharmaceuticals : Investor Day - Presentation | © 2017 Copyright. NMI Holdings Inc.
2020 Virtual Investor Day
Welcome to NMI Holdings, Inc. - 2020 Virtual Investor Day
Presentation materials will be displayed on screen alongside a video of management through each section of today's discu... |
25.02.2020 | The future of these 7 biotechs hinges on their ability to treat a silent liver disease and capture a $9.6 billion market. Here's exactly what investors should be watching for this year. | Reuters
Advertisement
There are about 70 drugs in clinical testing for NASH, a fatty liver disease that affects millions of Americans and is a top cause of liver transplants.
We identified seven biotechs that have staked their companies - a... |
18.07.2013 | NGM completes $50M Series C to advance cardio-metabolic therapies | NGM Biopharmaceuticals has rounded up a $50 million Series C financing to advance the development of its portfolio of therapeutics to treat diabetes, obesity, muscle wasting and other cardio-metabolic diseases.
The South San Francisco-based... |
18.07.2013 | NGM Biopharmaceuticals Inks $50M in Series C |
SOUTH SAN FRANCISCO, CA, NGM Biopharmaceuticals announced today the successful completion of a $50 million Series C financing.
>> Click here for more funding data on NGM Biopharmaceuticals
>> To export NGM Biopharmaceuticals... |
18.06.2013 | MedImmune and NGM Biopharmaceuticals link for research on diabetes and obesity | MedImmune and NGM Biopharmaceuticals link for research on diabetes and obesity
18-06-2013
AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an e... |
07.05.2013 | NGM raises $13M for cardio/metabolic R&D work | NGM Biopharmaceuticals has raised a little more than $13 million of a planned $50 million round, according to the San Francisco Business Times. The company, which includes Genentech legend Art Levinson on its board, has been engaged in basi... |
15.03.2010 | NGM Biopharmaceuticals Closes First Tranche of $51M Series B Financing | NGM Biopharmaceuticals, Inc., a South San Francisco, California-based company dedicated to the discovery and development of transformational medicines, has closed the first tranche of a $51m Series B round of financing.
The round included T... |
12.02.2008 | Life sciences briefing: Tuesday, Feb. 12, 2008 | TODAY’S HEADLINES:
Metabolic-disease biotech NGM Biopharma raises $25M (peHUB)
Heart, HIV drug maker Numerate acquires assets of Pharmix (release)
Next-gen sequencer VisiGen promises $1,000 genome by late 2009 (Genome Technology)
CalciMedic... |
- | NGM Biopharmaceuticals | “Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patien... |
- | NGM Bio’s NASH drug fails in Phase 2; focus shifts to Merck-partnered programs | An experimental NGM Biopharmaceuticals treatment for non-alcoholic steatohepatitis, the fatty liver disease more commonly referred to as NASH, has failed in clinical testing, a surprising result considering that an earlier mid-stage study s... |